PHF11 Inhibitors
PHF11 inhibitors comprise a diverse array of chemical entities that exert their inhibitory effects through the modulation of specific signaling pathways or biological processes that potentially interact with PHF11 function. LY294002 and Wortmannin, both PI3K inhibitors, act by suppressing the PI3K/Akt pathway, which is implicated in the activation of NF-κB-a transcription factor that could govern PHF11 expression. The blockade of this pathway by these inhibitors could consequently lead to a decrease in PHF11 activity. Similarly, MEK inhibitors such as PD98059 and U0126 impede the MAPK/ERK pathway, which plays a crucial role in cell proliferation and survival, thus potentially diminishing PHF11 expression through reduced transcriptional regulation. Inhibitors like SB203580 and SP600125, which selectively inhibit p38 MAPK and JNK, respectively, might modulate PHF11 activity indirectly by altering cellular responses to stress and inflammation that could impact PHF11 expression.
Compounds such as MG132, BAY 11-7082, and IKK-16 target the NF-κB signaling pathway by different mechanisms, all leading to a reduction in NF-κB-driven gene expression, which might include genes like PHF11. MG132 inhibits the proteasome, preventing the degradation of IκBα and consequently reducing NF-κB activity, while BAY 11-7082 directly inhibits the phosphorylation of IκBα. IKK-16, on the other hand, inhibits the IκB kinase, a key enzyme in the NF-κB activation cascade. Additionally, SB431542, by inhibiting the TGF-β type I receptor ALK5, and Cyclosporin A, by inhibiting calcineurin, both lead to alterations in immune response signaling pathways, which could indirectly diminish PHF11's functional role. Lastly, Rapamycin, an mTOR inhibitor, suppresses a pathway involved in cell growth and proliferation, where the downregulation of mTOR activity could influence the regulation of genes associated with these processes, potentially leading to lower PHF11 activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A potent inhibitor of phosphoinositide 3-kinases (PI3K), LY294002 leads to decreased PI3K signaling. PI3K is involved in the activation of NF-κB, which could regulate the expression of PHF11 by influencing the transcriptional activity. Inhibition of PI3K by LY294002 consequently could lead to reduced PHF11 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that irreversibly inhibits the kinase, leading to suppression of the PI3K/Akt pathway. As with LY294002, this suppression can reduce NF-κB activity, potentially decreasing the expression and activity of PHF11. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound is a selective inhibitor of p38 MAPK. The p38 MAPK pathway can be involved in the regulation of inflammatory responses and may indirectly influence the expression of genes like PHF11 by altering the cellular response to stress and inflammation. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that blocks the MAPK/ERK pathway. The MAPK/ERK pathway is implicated in cell proliferation and survival. Inhibition of this pathway can lead to decreased transcriptional regulation of various genes, possibly including PHF11. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), SP600125 can reduce AP-1 transcriptional activity, which is a potential regulator of PHF11 expression. This can indirectly diminish PHF11's function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can prevent the degradation of IκBα, an inhibitor of NF-κB. Stabilization of IκBα leads to reduced NF-κB activity, potentially decreasing PHF11 expression. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 irreversibly inhibits NF-κB activation by blocking the phosphorylation of IκBα. This results in diminished NF-κB-driven gene expression, which could include genes like PHF11. | ||||||
IKK 16 | 1186195-62-9 | sc-204009 sc-204009A | 10 mg 50 mg | $223.00 $942.00 | 2 | |
IKK-16 is an inhibitor of IκB kinase (IKK), which is pivotal in the NF-κB activation pathway. Inhibiting IKK can reduce NF-κB-mediated transcription, potentially leading to reduced PHF11 expression. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, preventing the activation of the MAPK/ERK pathway. This can lead to decreased transcription factor activity and possibly lower PHF11 expression levels. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542 selectively inhibits the TGF-β type I receptor ALK5, which is involved in the SMAD signaling pathway. TGF-β signaling can modulate immune responses, potentially affecting PHF11 expression indirectly. | ||||||